Mycosis Fungoides

4
Pipeline Programs
6
Companies
9
Clinical Trials
4 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 6 programs with unclassified modality

Competitive Landscape

6 companies ranked by most advanced pipeline stage

A
AngimmuneMD - Rockville
1 program
1
A-dmDT390-bisFvPhase 2
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
1
A-dmDT390-bisFvPhase 21 trial
Active Trials
NCT02943642UnknownEst. May 2020
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
1
Mogamulizumab-KpkcPhase 11 trial
Active Trials
NCT06235281Suspended20Est. Sep 2029
Novartis
NovartisBASEL, Switzerland
1 program
1
TulmimetostatPhase 1Small Molecule4 trials
Active Trials
NCT07190300Recruiting155Est. Jun 2032
NCT07206056Recruiting188Est. Dec 2030
NCT05944562Active Not Recruiting24Est. Jan 2029
+1 more trials
Recordati
RecordatiFrance - Saint-Victor
2 programs
ChlormethineN/A1 trial
The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult PatientsN/A1 trial
Active Trials
NCT05303480Completed32Est. Dec 2022
NCT06421571Recruiting40Est. Dec 2025
Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
1 program
3.75% Imiquimod CreamN/A1 trial
Active Trials
NCT02301494WithdrawnEst. Apr 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
City TherapeuticsA-dmDT390-bisFv
NovartisTulmimetostat
NovartisTulmimetostat
NovartisTulmimetostat
Kyowa Hakko KirinMogamulizumab-Kpkc
NovartisTulmimetostat
RecordatiThe Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients
RecordatiChlormethine
Bausch Health3.75% Imiquimod Cream

Clinical Trials (9)

Total enrollment: 734 patients across 9 trials

NCT02943642City TherapeuticsA-dmDT390-bisFv

Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides

Start: Jan 2017Est. completion: May 2020
Phase 2Unknown
NCT07190300NovartisTulmimetostat

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Start: Jan 2026Est. completion: Jun 2032155 patients
Phase 1/2Recruiting
NCT07206056NovartisTulmimetostat

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Start: Oct 2025Est. completion: Dec 2030188 patients
Phase 1/2Recruiting
NCT04104776NovartisTulmimetostat

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Start: Sep 2019Est. completion: Feb 2030275 patients
Phase 1/2Recruiting
NCT06235281Kyowa Hakko KirinMogamulizumab-Kpkc

Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT)

Start: Jan 2024Est. completion: Sep 202920 patients
Phase 1Suspended
NCT05944562NovartisTulmimetostat

Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome

Start: Jan 2024Est. completion: Jan 202924 patients
Phase 1Active Not Recruiting
NCT06421571RecordatiThe Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients

The Mechanism of Action of Chlormethine (CL) Gel in the Treatment of MF-CTCL Adult Patients

Start: Feb 2023Est. completion: Dec 202540 patients
N/ARecruiting
NCT05303480RecordatiChlormethine

Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides

Start: Dec 2021Est. completion: Dec 202232 patients
N/ACompleted
NCT02301494Bausch Health3.75% Imiquimod Cream

Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma

Start: Apr 2020Est. completion: Apr 2023
N/AWithdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 actively recruiting trials targeting 734 patients
6 companies competing in this space